A detailed history of Marshall Wace, LLP transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 240,387 shares of OLMA stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
240,387
Previous 588,996 59.19%
Holding current value
$1.29 Million
Previous $6.37 Million 54.96%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.41 - $16.46 $3.63 Million - $5.74 Million
-348,609 Reduced 59.19%
240,387 $2.87 Million
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $359,614 - $576,290
41,193 Added 7.52%
588,996 $6.37 Million
Q1 2024

May 15, 2024

BUY
$10.95 - $16.62 $2.82 Million - $4.27 Million
257,082 Added 88.43%
547,803 $6.2 Million
Q4 2023

Feb 14, 2024

BUY
$10.53 - $17.14 $2.15 Million - $3.5 Million
203,987 Added 235.19%
290,721 $4.08 Million
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $710,351 - $1.13 Million
86,734 New
86,734 $1.07 Million
Q1 2023

May 15, 2023

SELL
$2.55 - $4.97 $231,919 - $452,016
-90,949 Reduced 71.81%
35,700 $123,000
Q4 2022

Feb 14, 2023

SELL
$2.27 - $3.76 $45,819 - $75,895
-20,185 Reduced 13.75%
126,649 $310,000
Q3 2022

Nov 14, 2022

BUY
$2.72 - $5.88 $25,480 - $55,083
9,368 Added 6.81%
146,834 $404,000
Q2 2022

Aug 15, 2022

BUY
$2.04 - $4.61 $280,430 - $633,718
137,466 New
137,466 $558,000
Q1 2022

May 16, 2022

SELL
$3.89 - $9.43 $299,887 - $726,977
-77,092 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.75 - $30.71 $275,747 - $967,794
31,514 Added 69.14%
77,092 $721,000
Q3 2021

Nov 15, 2021

BUY
$22.96 - $30.13 $1.05 Million - $1.37 Million
45,578 New
45,578 $1.26 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $217M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.